Stockhub

BridgeBio Pharma, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 August 2022

12 August 2022

26 July 2022

  • curprev 21:4721:47, 26 July 2022‎ Chris talk contribs‎ 1,491 bytes +1,491‎ Created page with "BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM;..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/BridgeBio_Pharma,_Inc.’